Immunotherapy has reshaped cancer treatment over the past decade by teaching the body's own immune cells to hunt down tumors instead of relying solely on chemotherapy or radiation. Prostate cancer, though, has mostly sat outside that revolution. Most prostate tumors are what oncologists bluntly call "immune cold," meaning they barely attract the T cells that immunotherapy depends on to work at all. A study published June 16, 2026, in Nature Biomedical Engineering, led by researchers at Duke University School of Medicine and the University of Rochester Medical Center, describes a CRISPR-based fix aimed directly at that problem.

Why "cold" tumors leave immunotherapy with nothing to work on

Immune checkpoint therapy, the class of drugs that has driven much of the recent progress in cancer treatment, works by releasing molecular brakes that normally hold T cells back from attacking tumors. But releasing those brakes only matters if T cells can actually find the tumor in the first place. Malignant cells signal their presence to the immune system through a surface marker called MHC-1, essentially a flag that lets T cells recognize a cell as abnormal and worth attacking. Many prostate cancers suppress this flag, becoming functionally invisible to immune surveillance even when checkpoint inhibitor drugs are technically doing their job elsewhere in the body.

According to Eric J. Wagner, PhD, a professor of biochemistry and biophysics and co-director of the Center for RNA Biology at the University of Rochester Medical Center, that invisibility is precisely why immune checkpoint therapy alone tends to fail against prostate cancer. "The problem is that some cancers respond well to immunotherapy, but others develop resistance or don't respond at all," Wagner said, describing the gap this research was designed to close.

An RNA edit rather than a DNA cut

The technology behind the fix departs from how most people picture CRISPR working. Rather than cutting DNA or RNA outright, the research team built a CRISPR/Cas13-based system that binds to a specific section of messenger RNA without severing it. Their target was a gene called SPSB1, which in prostate cancer cells gets systematically shortened at the tail end of its mRNA transcript, called the 3′ untranslated region, or 3′UTR. That shortening, researchers found, is a driving mechanism behind the suppressed MHC-1 signal that makes these tumors immune-cold in the first place.

By preventing the SPSB1 mRNA from being shortened, the CRISPR/Cas13 tool restores the transcript to something closer to its natural length. With less truncated SPSB1 protein being produced as a result, MHC-1 expression on the surface of the cancer cells increases, effectively switching the flag back on.

What happened once the flag went back up

The results in mouse models were substantial. Once MHC-1 expression was restored, prostate tumors treated with the CRISPR tool showed a marked increase in immune checkpoint therapy's effectiveness, with significantly more T cells infiltrating the tumor tissue and going on to destroy cancer cells within it. Researchers described the underlying process using the shorthand "3′UTRCES," referring to the reversal of what they call driver alternative polyadenylation, the mechanism by which cancer cells shorten mRNA tails to suppress immune-detecting proteins in the first place. That reversal converted immune-cold tumors into immune-hot ones capable of overcoming resistance to checkpoint therapy, according to the study.

Just as important for any future clinical path, the research team conducted a thorough review of the data and found no detectable off-target effects from the experimental treatment, an early but meaningful safety signal for a gene-editing approach still in preclinical stages. Wagner described the underlying mechanism in blunt terms: "No one has ever done this before. It's an excellent preclinical model showing that mRNAs can be forced to re-lengthen and when they do, there's therapeutic benefit."

A delivery method built for the whole body, not just a lab dish

Beyond the CRISPR editing mechanism itself, the study also demonstrated a lipid nanoparticle delivery system, referred to in the research as LNP-delivered 3′UTRCES, capable of carrying the treatment to tumor tissue in a living organism rather than only in isolated cell cultures. That detail matters considerably for translating a laboratory finding into an actual therapy, since gene-editing tools that work well on cells in a dish frequently run into delivery obstacles once tested in a full biological system, where getting the treatment specifically to tumor tissue without broader side effects is often the harder half of the problem.

Cancer's evolutionary advantage, and a plan to outpace it

Wagner frames the broader ambition of this line of research in terms of outmaneuvering how cancer typically escapes treatment altogether. "Cancer is super smart at evolving, but it's not a magician," he said. "If we can hit it with immunotherapy and another synergistic drug that pumps up the immune response, we could potentially cure it. It won't be able to evolve fast enough." That framing reflects a broader strategy increasingly common in oncology research: rather than relying on a single mechanism a tumor might eventually adapt around, combining an RNA-editing tool that restores immune visibility with existing checkpoint therapy drugs creates two simultaneous pressures a tumor would need to escape at once.

Where this research goes next

The same University of Rochester team, alongside collaborators at Duke, has already secured pilot funding from Wilmot Cancer Institute and Roswell Park Comprehensive Cancer Center to test whether the same RNA-editing approach can be applied to pancreatic cancer, another tumor type notorious for resisting immunotherapy through similar immune-cold mechanisms. The research was funded by the National Cancer Institute at the National Institutes of Health, and the current findings remain confined to mouse models, meaning any path to human trials would still require substantial additional safety and efficacy testing.

Given that prostate cancer remains one of the most common cancers diagnosed in men worldwide, and immunotherapy has so far delivered limited benefit against it compared to other cancer types, a validated method for reversing tumor invisibility to the immune system, rather than simply intensifying existing treatments, represents a genuinely different lever for oncologists to eventually pull, assuming the approach continues to hold up as it moves toward human application.

---

*Sources cited in this article include the peer-reviewed study published June 16, 2026, in Nature Biomedical Engineering, and reporting from ScienceDaily, MedicalXpress, SciTechDaily, University of Rochester Medicine, and Ynetnews covering the July 2026 public release of the findings. All figures reflect reporting available as of July 27, 2026.*